(Q38169245)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313774%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313774%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

0 references

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313774%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313774%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Heleen Scheerens

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313774%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

John G Matthews

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313774%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

1 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313774%20AND%20SRC:MED&resulttype=core&format=json

Proceedings of the American Thoracic Society

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313774%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

10 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313774%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

S206-13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313774%20AND%20SRC:MED&resulttype=core&format=json

Lessons from 60 years of pharmaceutical innovation

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Redefining approaches to asthma: developing targeted biologic therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

21 January 2018

What is severe asthma?

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Current treatment of severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Asthma exacerbations: origin, effect, and prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

The global burden of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Monoclonal antibodies for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Trials and tribulations in identifying new biologic treatments for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

The potential of biologics for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Global strategy for asthma management and prevention: GINA executive summary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

New paradigms in type 2 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

A large subgroup of mild-to-moderate asthma is persistently noneosinophilic

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Analytical validation of a highly sensitive microparticle-based immunoassay for the quantitation of IL-13 in human serum using the Erenna immunoassay system

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

The cytokine network in asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Nitric oxide gas phase release in human small airway epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Exhaled nitric oxide measurements: clinical application and interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Asthma outcomes: biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Reslizumab for Poorly Controlled, Eosinophilic Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Lebrikizumab Treatment in Adults with Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Are exhaled nitric oxide measurements using the portable NIOX MINO repeatable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Serum level of the periostin, a homologue of an insect cell adhesion molecule, as a prognostic marker in nonsmall cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Periostin promotes chronic allergic inflammation in response to Th2 cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Periostin in fibrillogenesis for tissue regeneration: periostin actions inside and outside the cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Periostin is essential for cardiac healing after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Mepolizumab and exacerbations of refractory eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201303-047AW

10.1513/ANNALSATS.201303-047AW

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313774%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313774%20AND%20SRC:MED&resulttype=core&format=json